相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。A novel function of CXCL10 in mediating monocyte production of proinflammatory cytokines
Qihong Zhao et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2017)
CXCL10/IP-10 Neutralization Can Ameliorate Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome in Rats
Shan Lang et al.
PLOS ONE (2017)
Minimal physiologically-based pharmacokinetic (mPBPK) model for a monoclonal antibody against interleukin-6 in mice with collagen-induced arthritis
Xi Chen et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2016)
The underlying inflammatory chronic disease influences infliximab pharmacokinetics
Christophe Passot et al.
MABS (2016)
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
M. Rosario et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
A pharmacokinetic comparison of anrukinzumab, an anti- IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients
Fei Hua et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
IP-10/CXCL10 attracts regulatory T cells: Implication for pancreatic cancer
Serena Lunardi et al.
ONCOIMMUNOLOGY (2015)
A Tutorial on Target-Mediated Drug Disposition (TMDD) Models
P. Dua et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2015)
Mechanistic Pharmacokinetic/Target Engagement/Pharmacodynamic (PK/TE/PD) Modeling in Deciphering Interplay Between a Monoclonal Antibody and Its Soluble Target in Cynomolgus Monkeys
Weirong Wang et al.
AAPS JOURNAL (2014)
Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases
Alessandro Antonelli et al.
AUTOIMMUNITY REVIEWS (2014)
CXCR3, CXCL10 and type 1 diabetes
Alessandro Antonelli et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2014)
Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study
Lloyd Mayer et al.
GUT (2014)
Dose Selection Based on Physiologically Based Pharmacokinetic (PBPK) Approaches
Hannah M. Jones et al.
AAPS JOURNAL (2013)
Comparison of Nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model
Leonid Gibiansky et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2012)
The emerging role of CXCL10 in cancer (Review)
Mingli Liu et al.
ONCOLOGY LETTERS (2011)
Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Concepts and Lessons for Drug Development
Diane R. Mould et al.
BIODRUGS (2010)
Applying Physiological and Biochemical Concepts to Optimize Biological Drug Development
P. J. Lowe
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Target-mediated drug disposition model for drugs that bind to more than one target
Leonid Gibiansky et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2010)
Handling Data Below the Limit of Quantification in Mixed Effect Models
Martin Bergstrand et al.
AAPS JOURNAL (2009)
Pneumoviruses infect eosinophils and elicit MyD88-dependent release of chemoattractant cytokines and interleukin-6
Kimberly D. Dyer et al.
BLOOD (2009)
Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus
K. O. Kong et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics
Leonid Gibiansky et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
Approximations of the target-mediated drug disposition model and identifiability of model parameters
Leonid Gibiansky et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2008)
Blockade of interferon-γ-inducible protein-10 attenuates chronic experimental colitis by blocking cellular trafficking and protecting intestinal epithelial cells
Kenji Suzuki et al.
PATHOLOGY INTERNATIONAL (2007)
Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition
DE Mager et al.
PHARMACEUTICAL RESEARCH (2005)
A novel mechanism for the regulation of IFN-gamma inducible protein-10 expression in rheumatoid arthritis
R Hanaoka et al.
ARTHRITIS RESEARCH & THERAPY (2003)